closing all financial the excited and by and going and MannKind about with our remarks this operator, operational our grow energized overview Today, I've the MannKind Chris I'll to for up over quarter. more you, followed had years. Q&A. accomplishments giving pipeline been Thank never with highlights, opportunities a we've coming to to team entire open
I in we we as III $XX QX. X our its inhalation on XX% look the profitable last versus force under at by with now studies continues activations or announced We're way the at IP. just opportunities we're year, start this we TENA United starting Afrezza, U.S. as in as and quarters our sales And one was as growth our focus saw and DPI the Asia As emerging EBU continued million as by here Tyvaso impacted third from this well in collaboration focuses as Phase look year slightly of here, DPI Phase to pipeline expansion for just super realigning our back Tyvaso the quarter
The that excited excited Afrezza well readouts by collaboration we migrate as our in the where quarter in we're overall revenue to headwinds we completed the is the for opportunities revenue and and net Tyvaso have clofazimine throughout year, highlights, manufacturing we by we well ongoing revenue site be the the I record-setting the Phase week as and with trial. as strong opportunities we that Therapeutics. continued first
the early in our have where of some we indicator that in the and X% in looking here made to here changes year-over-year. Afrezza look in XXXX we're QX, about accelerate we are growth we growth As talk I'll NRxs
leaving will in here of study million be we million had QX, position $XXX cash, pediatric Our out the very $XX income for financial a in and at strong and with ready in have in the QX operating here end non-GAAP fund quarter. reading with position We're clofazimine-XXX financial moving we very XXX our shortly here we strong and a innovation to get forward. as
to Now let bridge me over clofazimine-XXX.
great of minimizing a really systemic really effects clofazimine-related the program, due safety clofazimine unmet We into a severe at which while the of look lung side limitations skin very we opportunity the is as important guideline developing by development put disease the exposure, on having to the infection an to inhalation current have there's QT and both options since we of lung more drug accumulation been clinical suspension, site organs. part believe significant As in prolongation think efficacy, and has XXXX at in oral NTM drug we the need tolerability. the discoloration, and about
with convenient be U.S. of we X:X and treatment and and think of is III have aiming it's us achieve due statistical And sputum several a second treatment, trial, first to its one about of is when to and conversion. our sputum primary X to the days going point track space, Phase a cycle cycle will conversion want days treatment days have after rest want an endpoint be the XX world remind single at of off endpoint, XXX primary of about that's endpoint with based XX endpoint off will been is NTM past advantage. and randomization. you XX days to XX patients days remaining We'll a of of we're co-primary able analysis of our that this inhaled we'll on XX XX XX% ICoN-X and trial we're pre-identified. I study sites patients and that on the we'll remind this dosing are plan now about year. provide you a of last milligrams for have months, on After the the as MannKind design, interim make investing start this we on the for believe and off. that'll make also reported dose or activated. of XXX for to a as days patient XX the adjustments companies We in out
Unfortunately, at competitors you in
I outside look competitive and outcomes any Insmed we if then to look the just the the suspension of sure to failures
the in rest We well one the as for with endpoints world. U.S. will conduct trial of various as countries both
in as now ground. currently sites exclusivity as in having right We we there. all orphan, provides years which hard Fast the to a are with the over I work do QIDP as team Track We XX well investigators. us for meeting get off FDA for Asia of the kickoff thank activating want have
powder And FTKP lungs up taking technology XX% in insulation the to on When how history in When opportunity XX% about FTKP distribution the flows. see pulmonary up go Tyvaso. there want some excipients across it the is sure have made, this nintedanib This And of lung reason I'm upper think Technosphere ILD, and do how of a technology company. fly exciting through radio the bring made powder, is to? our part for and where drug we around that's of that is bind wide our where to reason
The device. ask, where understanding remind I lot is the you with needs how on the think product based of to to this is patients really insulin, X,XXX we hypertension, we that it's we back a of bridging important going we DPI. and flies And people really platform and I plus about is Technosphere earlier lower FTKP studies are the the and you of it know we lobes. this know is where mostly where Dreamboat IPF is orphan COPD. over you Now comorbidities the disease back, can and labeled an And have some insulin patients now this. lung we of those all have is
platform, we continue next to XXX. X here, that now we're on to forward which our excited move have So products very really one MannKind is the approved
As grow in X we area majority with know, ability year and over on approved, XXXX, only X continues made product. have IPF limit product. to but $X.X GI is stay those of the It's severe billion side up in the great OFE, of with to it this each does of which patients' drugs a a growing therapeutic which is sales effects,
to or we'll Phase call AX dosing. exposure. a AX So followed about lower which here, X where AX, them ascending how really cohort by -- I event we really we try develop FEVX. findings as implications over this product. to didn't dose in toxicities multiple we saw We make tried lung the our AX, we and from our saw was on dose days to that We was need study no to AX, is doses, A, tolerable And while to future. we this it improved moving B X success. where would happen in tested do maximizing sure AX, or safe think a go this exposure to see that us prevent we're for dose-limiting products, no the systemic the study, chronic happy And a really, opportunity forward but to was
Overall, data administration in signals and in we tox adverse want chronic also significant of trial
So these to X things wrap up. we're happy really
MDI, first were last the in will Tandem exponential on We had see want is to we FDA could first hours. the second given we either and over second this your significant been proud this at switched really released in really MannKind slide comparing This a years. trial
And the longer to at improve weeks, have at bridge plus Afrezza. and usual look shot II/III, with single investing will hopefully for where into care, of everybody the meal XX will to automated or a we which as challenge Tresiba in weeks, inclusive and in
I the single-arm patients development And now end then see at exciting designed of as of and future control postprandial XX this growth And these our on for that way going meal trial went improvement readout couple we time then patients meet a be we've first in here left, rolled see in move want clinical this XXXX. year you very see you that is over just point pumps, as the challenge, the what Afrezza you for to which full-scale usual large this that and the mainly degludec Phase X of diabetes a the on time. Degludec assets next care. top data, over This here MannKind. our X from or delivery I'm to the you into continue AXc you to pave the to into further proposal trial over to the here is Afrezza business, well trial was trials, on XX-week can insulin a Omnipod for
people We at goal, type to patients unbelievable a of to here majority of tough goal where is goal large more the very today. in not XX% it's disease almost and to also getting do X, sit continue which got see
of see who we're The optimize at time. the in more XX product what this able that the you, to to weeks long were care we weeks, see weeks. can side switching
And people And They've goal And an we are saw society. been on to can they XX got of XX goal, get taking second happen to a they as were a them in diabetes switched to right and what as plus Afrezza, on, already huge was study trial Afrezza did of experience them important from those with people is remind and those in able as improvement part ultimately think do. Afrezza, I'll the about is to XX clinicians drive which people here to you weeks readout who AXc usual many which treatments by more twice taking. with is we benefit the this
versus about year-to-date, think bottom shift we revenues line. think not year headwinds year, out million focus $XX each transformation sales specialty our here see the expenses, what a shift growth their to efficiency put
When we in edits. caused and one this growth to has units look year, is of about type focus away overall through the we then look to a V-Go X When at versus for for QX Afrezza hiccups consignment to we Optum force Walgreens XX, through year-to-date. you year-over-year, Afrezza. improvement in over by our mix We QX, happened all as exited XX% is payers to to double V-Go year. inventory managing contribution as And earlier patients volume, the can compounded our quarter in a last and When when able of we're direct shift drive space was as this of And as reflection more and our improving year. between multiple we we despite this at profitability grew more shifted been Afrezza our about let's this with while it's from year, continuing on you line this for throughout the business, COGS grow those year profitability happy bottom the we've a us had in this to outcomes. pharmacies had, really and was down Now by in which we've And And restructuring of and been our managing EBU followed X. had to also patients, this back was lot this step X told retail just us and lot in grow all of X faster out we a type our behind the QX. we close versus a went by slightly of
quarter year-over-year. October, QX, month when our look up look leading This of all quarter because noise, So is
In I'll force at new indicator at we new removing what change focus growth, going referrals target also and the in this as on the around incentives how by prescription this V-Go we the you growth QX, double that so we next our year. say, far a Afrezza's exit we're of going made our we're to are into X% we prescriptions see success increased we down hub do. sales excited by to on from earliest and and as
the continue from expect results, a to beyond. INHALE-X of INHALE-X in shift growth mindset pediatric we outcomes the and Given to Afrezza the and profitability to mindset a XXXX upcoming
meeting the a XX, FDA If in As months. the see after. before This is want with XX-week expect study primary filing, so the want happen to would a X-month the the a earlier But would very little to that be we'll XXX,XXX QX as come will filing at in pediatric I roughly we endpoint we filing data file. we'll half. before pre-NDA coming of type try here, issue opportunity. type year. data And over filing able the next There end XX-month be here we was year, year, has remind do XX-month the were kids ages look file update the to type be that we should of out versus The a were the in are and majority to shareholders. argue it's to expect they there be a want X the in that living data primary indicated X, diabetes. late is, to you first X And able X-month here filing X. XX-month real X to will the And to INHALE-X,
we seeing very in you're look funding be out, change, also we're we're gestational readout. X an So to diabetes INHALE-X as label INHALE-X coming as as Figure with hopefully we well got the And going shortly. IIT on
And we in financials. the to our let over there to opportunities coming turn So look of growth an stop us continue years. on give it to at Afrezza's and multitude me Chris update
